Related Experiment Video
Updated: Jun 17, 2026
09:54
Chronic, Acute, and Reactivated HIV Infection in Humanized Immunodeficient Mouse Models
Published on: December 3, 2019
[BNP in HIV-infected patients]
Till Neumann1, Nico Reinsch, Kathrin Neuhaus
1Klinik für Kardiologie, Zentrum für Innere Medizin, Universitätsklinikum, Essen, Germany. till.neumann@uk-essen.de
Herz
|December 22, 2009
Summary
B-type natriuretic peptide (BNP) effectively detects cardiac disorders in HIV-infected patients. This biomarker aids in screening for HIV-associated cardiovascular conditions, improving patient outcomes.
Area of Science:
- Cardiology
- Infectious Diseases
- Biomarker Research
Context:
- HIV infection is linked to increased cardiac disease risk.
- Antiretroviral therapy can contribute to cardiovascular complications.
- Understanding cardiac risk in HIV patients is crucial.
Purpose:
- To evaluate the impact of B-type natriuretic peptide (BNP) in HIV-infected patients.
- To assess BNP's utility in detecting cardiac disorders within this population.
Summary:
- The prospective HIV-HEART study included 802 HIV-infected patients.
- BNP levels correlated with echocardiographic parameters, including right ventricular diameter and pulmonary arterial pressure.
- Elevated BNP (>50 pg/ml) was significantly associated with higher rates of heart failure, cardiomyopathy, and coronary artery disease.
Impact:
- BNP is a suitable biomarker for detecting cardiac disorders in HIV-infected individuals.
- BNP can be utilized in screening programs for HIV-associated cardiovascular conditions.
- This facilitates early detection and management of heart disease in the HIV population.
